OncoMatch/Clinical Trials/NCT06191133
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Is NCT06191133 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Fenofibrate for cervical intraepithelial neoplasia.
Treatment: Fenofibrate — Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Lab requirements
Kidney function
CrCl >30 mL/min; no end-stage kidney disease on dialysis
Liver function
Normal liver function (AST, ALT, bilirubin within institutional normal limits)
Normal liver function (AST, ALT, bilirubin within institutional normal limits). Participants with severe kidney impairment (CrCl ≤30 mL/min calculated using Cockcroft-Gault), or end-stage kidney disease on dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify